Halogenated Chalcone Compounds for Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hypoglycemic medications for diabetes and metabolic syndromes often come with severe side effects, such as diarrhea, anorexia, lactic acidosis, edema, body weight gain, and hepatotoxicity, necessitating the development of novel agents without these adverse effects.
Innovation Solution
Synthesis of novel chalcone compositions that promote glucose absorption and inhibit glycemia, specifically chalcone compounds with halogen substituents in ring A, which are effective in regulating and stabilizing blood glucose levels and inhibiting body weight gain and lipid droplet accumulation in adipocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional hypoglycemic medications (sulfonylurea, biguanides, AGI, TZDs, DPP-4 inhibitors) are used to treat diabetes, then blood glucose levels are reduced, but severe side effects occur (lactic acidosis, hepatotoxicity, edema, body weight gain)
Solution Approach 1:
The patent modifies the chemical structure of chalcone compounds by changing parameters such as introducing halogen substituents (fluoro, chloro, bromo, iodo) at specific positions (C-2, C-3, C-5, C-6) on the A-ring and various substituents (methoxy, hydroxyl, carboxyl, ester groups) on the B-ring. These structural parameter changes result in novel compounds with improved anti-hyperglycemic activity and reduced side effects compared to conventional medications.
Solution Approach 2:
The patent creates composite chalcone compounds by combining different functional groups and substituents on the chalcone backbone structure. The composite nature of these compounds (with multiple functional groups working synergistically) enables them to achieve effective glucose lowering while avoiding the harmful side effects of single-mechanism conventional drugs.
2Reliability
If insulin sensitizers (troglitazone, rosiglitazone, pioglitazone) are used to enhance peripheral tissue sensitivity to insulin, then glucose levels decrease, but adverse reactions occur (edema, body weight gain, congestive heart failure, hepatotoxicity)
Solution Approach 1:
The patent applies local quality modification by introducing specific functional groups at specific positions on the chalcone molecule. For example, placing electron-withdrawing groups (halogens, carboxyl, ester) at C-2 or C-3 on the A-ring and electron-donating groups (methoxy, hydroxyl) on the B-ring creates localized electronic effects that optimize binding to PPARγ while reducing off-target effects causing edema and weight gain.
Solution Approach 2:
The patent creates structural analogs of known PPARγ agonists (thiazolidinediones) using the chalcone scaffold. These copied structures maintain the core pharmacological activity of enhancing insulin sensitivity while differing sufficiently in their molecular structure to avoid the adverse effects associated with the original thiazolidinedione class.
3Reliability
If metformin (biguanide) is used to treat type 2 diabetes, then glucose production is reduced, but serious side effects occur (diarrhea, anorexia, vomit, lactic acidosis)
Solution Approach 1:
The patent replaces the mechanical/metabolic mechanism of metformin (inhibiting hepatic glucose production through AMPK activation) with a different molecular mechanism. The chalcone compounds act as PPARγ agonists, directly enhancing peripheral glucose uptake and utilization, thereby achieving glucose control through an alternative physiological pathway that avoids metformin's harmful side effects.
Data Source
AI summary
Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.